The European Medicines Agency (EMA) has recommended the use of Rytelo (imetelstat) for adult patients with transfusion-dependent anemia due to myelodysplastic syndromes, a group of cancers affecting blood cells in the bone marrow. These diseases can lead to fatigue, infections, and bleeding disorders, with a risk of developing acute myeloid leukemia. Imetelstat blocks telomerase activity, inhibiting cancer cell proliferation. The drug reduced the need for red cell transfusions in a study, leading to its marketing authorization recommendation by the EMA. Imetelstat’s orphan drug status provides benefits for the pharmaceutical company, based on its potential to benefit patients with myelodysplastic syndromes.
Source link
Rytelo Recommended in Europe for Myelodysplastic Syndromes
